A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial

Lancet Infectious Diseases
Jan 2018 Volume 18 Number 1 p1-122  e1-e32
http://www.thelancet.com/journals/laninf/issue/current

Articles
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
Increasing evidence shows that protection induced by acellular pertussis vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We aimed to assess the safety and immunogenicity of a recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin and filamentous haemagglutinin, as either a monovalent vaccine (aP[or in combination with tetanus and reduced-dose diphtheria vaccines (TdaP[versus a licensed tetanus and reduced-dose diphtheria and acellular pertussis combination vaccine (Tdap).
Sirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, Punnee Pitisuttithum, Jittima Dhitavat, Arom Pitisuthitham, Wanatpreeya Phongsamart, Kobporn Boonnak, Keswadee Lapphra, Yupa Sabmee, Orasri Wittawatmongkol, Pailinrut Chinwangso, Indrajeet Kumar Poredi, Jean Petre, Pham Hong Thai, Simonetta Viviani